Signal Transduct Target Ther April 2023 PMID 37069171

Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.

Qian Wang, Chenchen Yang, Li Yin, Jing Sun, Wei Wang, Hengchun Li, Zhengyuan Zhang, Si Chen, Bo Liu, Zijian Liu, Linjing Shi, Xiaolin Liu, Suhua Guan, Chunhua Wang, Linbing Qu

Download social card

Mentions

Peak: 40 in Apr 2023

across 4 sources since Apr 2023

Extended reach

136,152

potential audience

Total likes

186

Video views

Mentions per month

Apr 2023 – Jul 2023

Where it's discussed

X / Twitter40 posts
Reddit8 posts
Facebook2 posts
YouTube1 videos

AI synopsis

What people are saying

Discussions around the publication reveal a predominantly positive outlook, with posts emphasizing the broad protection offered and the novel intranasal approach. Phrases like 'broad mucosal and systemic immunity' and 'potentially helping to block infection and transmission' demonstrate recognition of significant scientific and public health implications, while expressions such as 'a promising booster' indicate strong interest and belief in its impact.

AgreementModerate agreement

Most discussions express support or curiosity about the study's findings, with some posts explicitly praising the potential benefits of the intranasal booster.

InterestHigh interest

Posts demonstrate high interest, highlighting the relevance of the research for future COVID-19 strategies and showing engagement with the innovative approach.

EngagementModerate engagement

Several comments reference specific aspects of the method, such as mucosal immunity and broad protection, indicating a moderate to deep level of engagement.

ImpactHigh impact

Many posts suggest that this research could significantly influence vaccine deployment strategies and public health, reflecting a perception of high potential impact.

Abstract in brief

The study developed an intranasal vaccine called Ad5SOmicron that produces strong immune responses specifically in the respiratory mucosa, including IgA antibodies and T cells, as well as systemic neutralizing antibodies against various Omicron subvariants and other SARS-CoV-2 strains.
When used as a booster in mice previously vaccinated with an ancestral inactivated vaccine, the intranasal Ad5SOmicron induced broad neutralization, including against newly emerged variants like XBB and BQ11, and provided protection against Omicron in mouse challenge tests.
The findings suggest that this intranasal Omicron-based booster could be an effective, safe, and easy-to-administer vaccine option to enhance mucosal and systemic immunity, potentially helping to block infection and transmission of multiple SARS-CoV-2 variants.

Read the full abstract

All mentions

Intranasal Omicron Booster Enhances Mucosal and Systemic Immunity

This study developed an intranasal vaccine, Ad5SOmicron, that triggers strong mucosal and systemic immune responses, including IgA antibodies and T cells, boosting protection against SARS-CoV-2 variants, especially…

Medicine RTCL TV · Jul 28, 2023 14 views

melinabaileyharris

@melina_b_harris · X